Back to Search
DEMETRIOS KATSAROS, M.D.
M.D.
Specialist
NPI: 1770610180IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
01049411(IN)
Education
CHICAGO COLLEGE OF MEDICINE AND SURGERY
Class of 1990
Research & Publications (20)
Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
PMID 15668288·Ann Oncol·2005
3-trial
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer.
PMID 15350359·Gynecol Oncol·2004
8-other
Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
PMID 12845660·Int J Cancer·2003
8-other
[Expression and prognostic significance in epithelial ovarian cancer].
PMID 11828267·Minerva Ginecol·2002
8-other
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival.
PMID 11267857·Eur J Cancer·2001
8-other
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
PMID 19322891·Cancer·2009
8-other
Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.
PMID 19172191·PLoS One·2009
7-preclinical
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
PMID 19179095·Crit Rev Oncol Hematol·2009
8-other
Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population.
PMID 19538958·Exp Cell Res·2009
8-other
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2).
PMID 19509559·Int J Gynecol Cancer·2009
3-trial
Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics.
PMID 18481170·Breast Cancer Res Treat·2009
8-other
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II.
PMID 19477633·Eur J Cancer·2009
8-other
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
PMID 18932017·Breast Cancer Res Treat·2009
8-other
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.
PMID 19181826·Ann Oncol·2009
3-trial
TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival.
PMID 18827819·Br J Cancer·2008
8-other
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
PMID 18761742·BMC Cancer·2008
8-other
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.
PMID 18458333·Proc Natl Acad Sci U S A·2008
8-other
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
PMID 18347175·Clin Cancer Res·2008
4-observational
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.
PMID 19074899·Cancer Res·2008
8-other
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
PMID 19033573·J Natl Cancer Inst·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7863 BROADWAY, STE 135
MERRILLVILLE, IN 46410 - Phone
- (219) 736-2047
Quick Facts
- NPI
- 1770610180
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile